Latham & Watkins advises ChemoCentryx in its US$3.7 billion acquisition by Amgen

The Sponsor

Loading page...

Latham & Watkins advises ChemoCentryx in its US$3.7 billion acquisition by Amgen | The Sponsor - The Sponsor